Literature DB >> 11956302

Beta IGH3, a TGF-beta inducible gene, is overexpressed in lung cancer.

Hidefumi Sasaki1, Yoshihiro Kobayashi, Yoshiaki Nakashima, Satoru Moriyama, Haruhiro Yukiue, Masahiro Kaji, Masanobu Kiriyama, Ichiro Fukai, Yosuke Yamakawa, Yoshitaka Fujii.   

Abstract

BACKGROUND: Transforming growth factor-beta (TGF-beta) is capable of affecting the proliferation of many cell types. beta IGH3, TGF-beta inducible gene, was originally isolated from lung adenocarcinoma cell line (A549). We have hypothesized that beta IGH3 mRNA levels could be predictors of the development and invasion of lung cancer.
METHODS: The study included 71 lung cancer cases. The beta IGH3 mRNA levels were quantified by real time reverse transcription polymerase chain reaction (RT-PCR) using LightCycler.
RESULTS: The beta IGH3 mRNA levels were elevated in tumor tissues from lung cancer (1.058 +/- 1.212) compared with non-malignant lung tissues (0.304 +/- 0.159) (p = 0.0001). No significant difference in beta IGH3 mRNA levels was found among gender, age, pathological subtype and lymph node metastasis. The beta IGH3 mRNA levels were elevated in tumor tissues from T4 lung cancer (1.425 +/- 1.470) compared with those from T1 lung cancer (0.702 +/- 0.655) (p = 0.05) and T2 lung cancer (0.736 +/- 0.734) (p = 0.044).
CONCLUSION: Using the LightCycler RT-PCR assay, the determination of beta IGH3 mRNA level might provide a potential marker for the aggressiveness of lung cancer. However, further studies and a longer follow-up are needed to confirm the impact of beta IGH3 on the biological behavior of the tumor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11956302     DOI: 10.1093/jjco/hyf021

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  7 in total

Review 1.  Evolving cancer-niche interactions and therapeutic targets during bone metastasis.

Authors:  Robert L Satcher; Xiang H-F Zhang
Journal:  Nat Rev Cancer       Date:  2021-10-05       Impact factor: 69.800

2.  Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors.

Authors:  Sergey V Ivanov; Alla V Ivanova; Konstantin Salnikow; Olga Timofeeva; Malayannan Subramaniam; Michael I Lerman
Journal:  Biochem Biophys Res Commun       Date:  2008-03-24       Impact factor: 3.575

3.  TGF-β-induced (TGFBI) protein in melanoma: a signature of high metastatic potential.

Authors:  Laura Lauden; Johan Siewiera; Wahid Boukouaci; Kiran Ramgolam; Samia Mourah; Celeste Lebbe; Dominique Charron; Fawzi Aoudjit; Nabila Jabrane-Ferrat; Reem Al-Daccak
Journal:  J Invest Dermatol       Date:  2014-01-17       Impact factor: 8.551

4.  Identification and characterization of transforming growth factor beta-induced in circulating tumor cell subline from pancreatic cancer cell line.

Authors:  Taku Sato; Tomoki Muramatsu; Minoru Tanabe; Johji Inazawa
Journal:  Cancer Sci       Date:  2018-09-21       Impact factor: 6.716

5.  TGFBI Promoter Methylation is Associated with Poor Prognosis in Lung Adenocarcinoma Patients.

Authors:  Yangki Seok; Won Kee Lee; Jae Yong Park; Dong Sun Kim
Journal:  Mol Cells       Date:  2019-01-24       Impact factor: 5.034

Review 6.  Transforming growth Factor-Beta-Induced Protein (TGFBI)/(βig-H3): a matrix protein with dual functions in ovarian cancer.

Authors:  Miranda P Ween; Martin K Oehler; Carmela Ricciardelli
Journal:  Int J Mol Sci       Date:  2012-08-21       Impact factor: 6.208

7.  Clinical implications of transforming growth factor-beta-induced gene-h3 protein expression in lung cancer.

Authors:  Changjun He; Dawei Sun; Xue Bai; Yingbin Li; Hai Xu; Shidong Xu
Journal:  Onco Targets Ther       Date:  2016-08-11       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.